INCY is trading 4% up at $108.59 as investors continue to buy into its strong recent earnings and pipeline story despite concerns about a 2028 patent cliff.
- The move extends a sharp rebound over the past week, fueled by a significant first-quarter earnings surprise.
- Sentiment remains supported by optimism that new drug candidates can successfully offset future revenue pressure from upcoming patent expirations.